๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Neoplasms
Clinical trial register · Australia

Breast Neoplasms Trials in Australia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3331 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:46 UTC
3331
Studies in scope
all four open statuses
1807
Recruiting now
open to new participants
758
Lead sponsors
across recruiting studies
Top sites
Melbourne 6 Darlinghurst 4 Westmead 4 Frankston 4 Clayton 4
Narrow the registerReset
Recruitment status
Phase
Site location
Melbourne6 Darlinghurst4 Westmead4 Frankston4 Clayton4
All 31 locations
Target enrolment
to

Breast Neoplasms trials in Australia

13 of 3331 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
800
Ballarat Central, Brisbane, Darlinghurst, Hobart, Melbourne, Newcastle, North Ryde, Shepparton
2025-12-22
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
BioNTech SE
Phase 3
558
Darlinghurst, Adelaide, Frankston, Melbourne, Westmead
2025-10-30
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Blacktown, Camperdown, Clayton, Melbourne, Nedlands
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Camperdown, North Ryde, Westmead, Clayton
2025-06-30
Active, closed
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453Breast Cancer, Breast Neoplasms
Pfizer
Phase 1/2
74
Blacktown, Brisbane, St Albans
2025-06-30
Active, closed
A Study of DM001 in Patients With Advanced Solid Tumors
NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1
128
South Brisbane, Southport, Clayton
2024-10-24
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Frankston, Mount Waverley, Melbourne
2024-05-20
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Ballarat Central, Box Hill, Clayton, Coffs Harbour, Darlinghurst, Geelong, Hobart, Launceston
2022-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Darlinghurst, Woolloongabba, Kurralta Park, Box Hill, Melbourne
2021-10-04
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Macquarie Park, Westmead, Frankston, Nedlands
2021-06-18
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
Eli Lilly and Company
Phase 3
669
South Brisbane, Southport, Kurralta Park, East Bentleigh, Subiaco
2014-07-22
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-australia/condition/breast-neoplasms

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,331 studies in total at the last sync on 26 Sep 2026, 19:46 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Breast Neoplasms.

How many Breast Neoplasms trials are recruiting in Australia?

6 of the 13 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:46 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Neoplasms), 13 studies
PhaseStudiesRecruitingShare
Phase 39569.2%
Phase 1107.7%
Phase 1/2107.7%
Phase 2107.7%
Phase 2/3117.7%

Most active sponsors

Lead sponsors with the most studies (Breast Neoplasms)
Lead sponsorStudiesRecruiting
Eli Lilly and Company41
Merck Sharp & Dohme LLC43
BioNTech SE11
Bristol-Myers Squibb11
Pfizer10
Seagen, a wholly owned subsidiary of Pfizer10
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.